Adult Fibroblast Transdifferentiation for Ischemic Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating ischemic diseases, such as lower limb ischemia, ischemic heart disease, and ischemic cerebrovascular disease, face limitations due to the need for biocompatible vascular endothelial cells, which are challenging to derive from embryonic or induced pluripotent stem cells, and existing transdifferentiation methods fail to convert adult cells into endothelial cells effectively.
Innovation Solution
The method involves transducing adult fibroblasts with specific genes, including Er71, Klf2, Tal1, and Foxo1, to induce transdifferentiation into vascular endothelial cells, which can then be used to treat ischemic diseases by promoting angiogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vascular endothelial cells are derived from embryonic or induced pluripotent stem cells, then biocompatible vascular endothelial cells can be obtained, but the derivation process is challenging and complex
Solution Approach 1:
The invention changes the fundamental parameter of cell source from embryonic/induced pluripotent stem cells to adult fibroblasts. By using adult fibroblasts as starting material and applying specific transdifferentiation protocols with defined transcription factors (Er71, Klf2, Tal1, Foxo1), the method achieves biocompatible endothelial cell generation while dramatically simplifying the derivation process and avoiding the complexities of pluripotent stem cell culture and differentiation.
Solution Approach 2:
The invention extracts and utilizes specific transcription factors (Er71, Klf2, Tal1, Foxo1) that are critical for endothelial cell fate determination. By isolating and overexpressing these key regulatory molecules in adult fibroblasts, the method directly induces transdifferentiation into endothelial cells, bypassing the need for complex pluripotent stem cell derivation and differentiation protocols.
2Adaptability or versatility
If existing transdifferentiation methods are used, then cell type conversion can be attempted, but they fail to convert adult cells into endothelial cells effectively
Solution Approach 1:
The invention identifies and changes the critical parameters of transdifferentiation by selecting the specific combination of transcription factors (Er71, Klf2, Tal1, Foxo1) that are necessary and sufficient for converting adult fibroblasts into endothelial cells. This specific parameter combination overcomes the failure of existing methods by targeting the precise molecular pathway required for endothelial cell fate specification.
Solution Approach 2:
The invention uses viral vectors as intermediaries to deliver the transdifferentiation-inducing transcription factors into adult fibroblasts. The viral vector system efficiently transduces the target cells with the required genetic material, enabling reliable and effective transdifferentiation that was not achievable with previous methods.
3Productivity
If adult fibroblasts are transduced with specific genes to induce transdifferentiation, then functional vascular endothelial cells can be produced, but the transdifferentiation process requires precise genetic manipulation
Solution Approach 1:
The invention merges multiple critical transcription factors (Er71, Klf2, Tal1, Foxo1) into a single transduction protocol using viral vectors. By combining these factors in one genetic manipulation step rather than sequentially introducing them, the method achieves efficient transdifferentiation while reducing the overall complexity of the genetic manipulation process.
Solution Approach 2:
The transduced adult fibroblasts, once introduced with the transcription factor genes, autonomously undergo transdifferentiation into functional endothelial cells without requiring continuous external intervention. The introduced genetic elements self-regulate to drive the differentiation process, reducing the need for complex external control mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The transdifferentiated vascular endothelial cells exhibit functional and genetic profiles similar to native endothelial cells, effectively promoting angiogenesis and salvaging ischemic limbs, offering a novel treatment approach for ischemic diseases.
Implementation Method 1
a method of preparing vascular endothelial cells by transdifferentiating target cells, the method comprising a step of transducing the target cells with genes, wherein the genes comprise Er71 and Klf2
Data Source
AI summary
The present invention relates to a method of preparing vascular endothelial cells by transforming (transdifferentiating) adult fibroblasts and a composition, which includes vascular endothelial cells prepared according to the method, for preventing and treating ischemic diseases, the method including a step of transducing adult fibroblasts with a gene. In particular, the present invention confirms that five factors, Foxo1, Er71, Klf2, Tal1, and Lmo2, induce transdifferentiation of adult fibroblasts into induced vascular endothelial cells. Furthermore, the present invention confirms that three factors, Er71, Klf2, and Tal1 induce transdifferentiation of human adult fibroblasts into induced vascular endothelial cells. The resultant induced endothelial cells enable lower limb salvaging by angiogenesis in lower limb ischemic animal models, showing that the induced endothelial cells can be effectively used for prevention or treatment of ischemic diseases.